The U.S. Patent and Trademark Office has received significant feedback on its proposal to streamline the invalidation of follow-on patents. This move has garnered varied responses, with advocates of reduced drug pricing welcoming the proposal. Conversely, [top technology and pharmaceutical companies have expressed opposition](https://www.law360.com/articles/1835688/drug-pricing-overreach-dominate-ip-disclaimer-feedback), and high-profile officials have flagged the proposal as an overreach of the agency’s authority. These developments underscore the contentious nature of intellectual property regulation in the pharmaceutical sector.